Robert N. Wilson
Known title: DirectorCIK: 0001189022
Robert N. Wilson's purchase track record
How the stock did after each of Robert N. Wilson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since December 11, 2023
Stock higher 6 months later
40%
3 months: 60%
Median 6-month return
-4.4%
3 months: +6.6%
Beat the S&P 500
40%
median -14.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/18/2025 | CALC | $13K | +6.6% | +70.4% | +10.2% |
| 11/1/2024 | CALC | $200K | -27.1% | -50.1% | -0.7% |
| 8/23/2024 | CALC | $201K | -14.0% | -41.4% | +6.7% |
| 6/27/2024 | CALC | $208K | +43.5% | -4.4% | +10.1% |
| 12/11/2023 | CALC | $2K | +32.2% | +51.0% | +16.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CALC | ▲ Buy | Grant | 1,182,621 | $950K | 6/25/2026 | View on chart |
| CALC | ▲ Buy | Open Market | 4,500 | $13K | 7/18/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 53,333 | $200K | 11/1/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 54,000 | $201K | 8/23/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 51,278 | $180K | 6/28/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 8,443 | $27K | 6/27/2024 | View on chart |
| CALC | ▲ Buy | Grant | 68,314 | $291K | 1/23/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 506 | $2K | 12/11/2023 | View on chart |
| CALC | ▲ Buy | Grant | 181,655 | — | 3/20/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.